Fortrea reported third quarter 2026 financial results with earnings and revenues surpassing estimates, completed a $45 million acquisition of Worldwide Clinical Trials' Early Phase Services divisions, and updated full-year guidance.

• Fortrea reported third quarter 2026 earnings and revenues surpassing estimates and updated full-year guidance [N2][N3].
• The company completed a $45 million acquisition of Worldwide Clinical Trials' Early Phase Services divisions in October 2026 [N4].
• The acquisition deal was announced in September 2026 and completed in October 2026 [N5][N4].
• Fortrea held its Q3 2026 earnings call on October 29, 2026 [N1].
• Fortrea's Q2 2026 earnings call transcript was published in August 2026 [N6].
• Fortrea surpassed Q2 2026 earnings and revenue estimates [N7].
• Zacks Investment Ideas highlighted Fortrea among other biotech stocks in July 2026 [N8].

Fortrea operates in a large and growing clinical development market with increasing pharmaceutical and biotechnology R&D spending and elevated outsourcing levels. Its flexible service delivery models and investments in AI and advanced technologies support operational agility and quality. The acquisition of Worldwide Clinical Trials' Early Phase Services divisions expands its capabilities in early phase clinical trials. The company's broad therapeutic expertise and global footprint enable it to capture diverse clinical trial opportunities. Positive recent financial results and maintained liquidity provide a foundation for continued operational execution.

Risks include dependence on generating new business awards and potential delays or reductions in contract scope. Challenges in patient recruitment and enrollment could impact operations. International operations expose the company to additional risks and expenses. Customer and therapeutic area concentration may affect financial performance. Funding constraints among customers could limit clinical trial activity. Backlog may not fully convert to revenue. Retention of qualified personnel and reliance on third parties for critical services pose operational risks. Regulatory compliance and data access challenges could adversely affect the business. Integration risks exist with strategic acquisitions.

Fortrea's competitive advantages stem from its global scale, extensive therapeutic expertise, and flexible delivery models tailored to customer needs. Its integrated clinical pharmacology units with on-site cGMP pharmacies and investments in AI and advanced technologies enhance operational efficiency and data quality. The company's broad therapeutic focus and ability to serve large and small customers across multiple geographies position it well within the growing CRO market. The recent acquisition of Worldwide Clinical Trials' Early Phase Services divisions further strengthens its service offerings and market presence. Fortrea's spin-off from Labcorp and focused strategy on clinical services contribute to its specialized market positioning.

• Dependence on New Business Awards: The company’s financial performance may be materially affected if it does not generate a large number of net new business awards or if awards are delayed, terminated, reduced in scope, or fail to go to contract [S1].
• Patient Recruitment and Enrollment Challenges: Inability to contract with suitable investigators and recruit and enroll patients for clinical trials could negatively impact operations [S1].
• International Operations Risks: Operating in approximately 100 countries exposes the company to additional risks and expenses that could adversely affect business or results [S1].
• Customer and Therapeutic Area Concentration: Concentrations may have a material adverse effect on business, financial condition, results of operations, or cash flows [S1].
• Customer Funding Constraints: Customers may experience insufficient funding to complete clinical trials, impacting demand for services [S1].
• Backlog Realization Risk: Backlog might not be indicative of future revenues and may not fully convert to anticipated revenue [S1].
• Personnel Retention and Costs: An inability to attract and retain experienced and qualified personnel, including key management, and increased personnel costs could adversely affect the business [S1].
• Third-Party Dependencies: Dependence on third parties for critical services and compliance with laws and regulations poses operational risks [S1].
• Data Access Risks: Inability to access necessary data from partners on commercially reasonable terms or at all could adversely affect the business [S1].
• Internal Controls: Failure to maintain effective internal controls could materially adversely affect business, financial condition, results of operations, and cash flows [S1].
• Regulatory Compliance Risks: Failure to comply with pharmaceutical and medical device regulatory agencies, privacy and security laws, and other applicable laws could result in sanctions, penalties, and reputational damage [S1].
• Strategic Transaction Risks: Failure to identify, close, and integrate strategic acquisitions or transactions could adversely affect business objectives, revenues, and profitability [S1].

• Fortrea Holdings Inc. is a global contract research organization (CRO) providing biopharmaceutical product and medical device development solutions including phase I-IV clinical trial management, clinical pharmacology, and consulting services to pharmaceutical, biotechnology, and medical device customers [S1].
• The company operates in one reporting segment: Clinical Services [S1].
• Fortrea has approximately 14,300 employees and operates in about 100 countries [S1].
• The company offers flexible delivery models: Full Service, Functional Service Provider (FSP), and Hybrid, tailored to customer needs [S1].
• Fortrea's Clinical Pharmacology services include first-in-human and exploratory studies, supported by clinical research units (CRUs) with cGMP pharmacies in Leeds, Dallas, Daytona, and Madison [S1].
• Clinical Development is the largest revenue contributor, offering comprehensive services including regulatory affairs, protocol design, patient recruitment, project management, data management, pharmacovigilance, medical writing, and mobile clinical services [S1].
• Fortrea invests in AI, machine learning, advanced technologies, and workflow automation to enhance clinical research speed, quality, and patient safety [S1].
• The company focuses on therapeutic areas such as oncology, CNS and neurodegenerative diseases, metabolic disorders, immunology and inflammation, rare diseases, cell and gene therapies, cardiovascular, nephrology, infectious diseases, dermatology, ophthalmology, respiratory, and women's health [S1].
• Fortrea completed a $45 million acquisition of Worldwide Clinical Trials' Early Phase Services divisions in October 2026, expanding its early phase service capabilities [N4].
• The acquisition deal was announced in September 2026 and completed in October 2026 [N5][N4].
• Fortrea reported third quarter 2026 financial results with earnings and revenues surpassing estimates, and updated full-year guidance [N2][N3].
• The company reported net income of $600,000 and basic and diluted EPS of $0.01 for the quarter ended September 30, 2026, according to the 10-Q filing [S2].
• As of September 30, 2026, Fortrea had cash and cash equivalents of $220.6 million, current assets of $952.7 million, current liabilities of $983.3 million, a current ratio of 0.97, and a cash ratio of 0.22 [S2].
• There have been no material changes to risk factors since the 2026 10-K filing, which include risks related to new business awards, patient recruitment, international operations, customer concentration, funding availability, backlog realization, personnel retention, third-party dependencies, data access, internal controls, regulatory compliance, and strategic transactions [S1][S2].
• Fortrea was spun off from Labcorp Holdings Inc. in June 2023 and operates as a standalone publicly traded company [S1].
• The company sold its Enabling Services segment in the second quarter of 2024 [S1].